Header Logo

Connection

VIVEK SUBBIAH to Drug Resistance, Neoplasm

Back to Details
This is a "connection" page, showing publications VIVEK SUBBIAH has written about Drug Resistance, Neoplasm.
VIVEK SUBBIAH
Connection Strength
1.341
Drug Resistance, Neoplasm
  1. Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. J Natl Cancer Inst. 2017 10 01; 109(10).
    View in: PubMed
    Score: 0.232
  2. Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report. Proc Natl Acad Sci U S A. 2016 Mar 15; 113(11):E1419-20.
    View in: PubMed
    Score: 0.207
  3. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent?) a VEGFR2/PDGFR?/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. J Hematol Oncol. 2014 Aug 01; 7:52.
    View in: PubMed
    Score: 0.186
  4. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS One. 2011 Apr 06; 6(4):e18424.
    View in: PubMed
    Score: 0.148
  5. Immunotherapy in non-small cell lung cancer harbouring driver mutations. Cancer Treat Rev. 2021 05; 96:102179.
    View in: PubMed
    Score: 0.074
  6. Dual inhibition of BRAF and mTOR in BRAFV600E -mutant pediatric, adolescent, and young adult brain tumors. Cold Spring Harb Mol Case Stud. 2020 08; 6(4).
    View in: PubMed
    Score: 0.071
  7. Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends Cancer. 2020 09; 6(9):797-810.
    View in: PubMed
    Score: 0.070
  8. State-of-the-Art Strategies for Targeting RET-Dependent Cancers. J Clin Oncol. 2020 04 10; 38(11):1209-1221.
    View in: PubMed
    Score: 0.068
  9. Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors. Clin Cancer Res. 2018 01 01; 24(1):43-51.
    View in: PubMed
    Score: 0.058
  10. Towards precision oncology in RET-aberrant cancers. Cell Cycle. 2017 05 03; 16(9):813-814.
    View in: PubMed
    Score: 0.056
  11. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest New Drugs. 2015 Jun; 33(3):700-9.
    View in: PubMed
    Score: 0.049
  12. Exceptional responders: in search of the science behind the miracle cancer cures. Future Oncol. 2015; 11(1):1-4.
    View in: PubMed
    Score: 0.048
  13. Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. J Clin Oncol. 2010 Aug 20; 28(24):e415.
    View in: PubMed
    Score: 0.035
  14. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst. 2016 12; 108(12).
    View in: PubMed
    Score: 0.013
  15. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Mol Cancer Ther. 2016 10; 15(10):2475-2485.
    View in: PubMed
    Score: 0.013
  16. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology. 2016; 90(6):339-46.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.